Opthea 将来の成長

Future 基準チェック /56

Optheaは、61.9%と51.7%でそれぞれ年率61.9%で利益と収益が成長すると予測される一方、EPSはgrowで67.8%年率。

主要情報

61.9%

収益成長率

67.8%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	51.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	04 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Nov 07

Opthea GAAP EPS of -$0.26 misses by $0.03

Aug 30

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Aug 15

業績と収益の成長予測

NasdaqGS:OPT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	225	55	-67	-44	8
6/30/2026	72	-104	-79	-29	9
6/30/2025	6	-173	-167	-171	9
6/30/2024	0	-220	-161	-161	N/A
3/31/2024	0	-191	-141	-141	N/A
12/31/2023	0	-162	-121	-121	N/A
9/30/2023	0	-152	-121	-121	N/A
6/30/2023	0	-143	-121	-121	N/A
3/31/2023	0	-137	-116	-116	N/A
12/31/2022	0	-132	-112	-112	N/A
9/30/2022	0	-113	-92	-92	N/A
6/30/2022	0	-93	-71	-71	N/A
3/31/2022	0	-75	-64	-64	N/A
12/31/2021	0	-57	-56	-56	N/A
9/30/2021	0	-51	-51	-51	N/A
6/30/2021	0	-45	-46	-46	N/A
3/31/2021	0	-39	-36	-36	N/A
12/31/2020	0	-31	-27	-27	N/A
9/30/2020	0	-21	-16	-16	N/A
6/30/2020	0	-11	-6	-6	N/A
3/31/2020	0	-10	-7	-7	N/A
12/31/2019	0	-12	-10	-10	N/A
9/30/2019	0	-13	-13	-13	N/A
6/30/2019	0	-15	-17	-17	N/A
3/31/2019	0	-13	-14	-14	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	0	-12	-13	-13	N/A
6/30/2018	0	-13	-15	-15	N/A
3/31/2018	0	-12	N/A	-13	N/A
12/31/2017	0	-12	N/A	-11	N/A
9/30/2017	0	-8	N/A	-8	N/A
6/30/2017	0	-5	N/A	-5	N/A
3/31/2017	0	-5	N/A	-4	N/A
12/31/2016	0	-5	N/A	-3	N/A
9/30/2016	0	-5	N/A	-3	N/A
6/30/2016	0	-5	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	0	-4	N/A	-4	N/A
3/31/2015	1	-4	N/A	-4	N/A
12/31/2014	1	-4	N/A	-4	N/A
9/30/2014	1	-4	N/A	-4	N/A
6/30/2014	1	-4	N/A	-4	N/A
3/31/2014	1	-3	N/A	-4	N/A
12/31/2013	1	-2	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OPTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: OPT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: OPT今後 3 年以内に収益を上げることが予想されます。

収益対市場: OPTの収益 ( 51.7% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: OPTの収益 ( 51.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OPTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Opthea 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

Opthea Limited Announces Board Changes

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Opthea Limited Announces Executive Changes

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Opthea Limited Announces Board Changes

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘